Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 301–400 of 1,006
Tomioka, I., Ishibashi, H., Minakawa, E. N., Motohashi, H. H., Takayama, O., Saito, Y., Popiel, H. A., Puentes, S., Owari, K., Nakatani, T., et al. (2017) · eNeuro · doi:10.1523/eneuro.0250-16.2017 · Cited by 88
“These limitations have resulted in the failure to predict the efficacy of clinical trials in human patients from the experimental findings obtained from rodent models of neurodegenerative diseases, lessening the preclinical value of rodent models (Doody et al. 2013, 2014; Salloway et al. 2014).”
BackgroundBrody, A. H., & Strittmatter, S. M. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 86
“Finally, while immunotherapy with antibodies raised against Aβ has been shown to reduce plaque burden in AD patients, such interventions have failed to improve patient outcome (Doody et al., 2013, 2014; Holmes et al., 2008; Salloway et al., 2014; reviewed by Spires-Jones & Hyman, 2014).”
BackgroundENGAGE and EMERGE: Truth and consequences?
Kuller, L. H., & Lopez, O. L. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12286 · Cited by 83
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 85
Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease
Ross, J. A., McGonigle, P., & Van Bockstaele, E. J. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.09.002 · Cited by 84
Biomarkers in the diagnosis and management of Alzheimer’s disease
Wurtman, R. J. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.034 · Cited by 97
Clark, I. A., & Vissel, B. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13181 · Cited by 84
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
“However, the results were not convincing as the antibody failed to prevent a decline in cognition and functional ability [62].”
ResultUddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86
“In addition to this, as compared with other approved AChEIs, donepezil is also effective in improving AD-linked functional and cognitive deficit with comparable tolerability and safety [78].”
BackgroundYang, J., Li, S., He, X.-B., Cheng, C., & Le, W. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0106-3 · Cited by 83
Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
Marr, R. A., & Hafez, D. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00187 · Cited by 83
Two decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 83
Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0174-1 · Cited by 83
“The solanezumab phase 3 trials [10] showed no placebo-treatment differences in cognition; however, the ‘placebo’ (the majority of patients were treated with ChEIs and/or memantine) group with mild AD deteriorated, on average, 5.”
Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia
Liu-Seifert, H., Siemers, E., Sundell, K., Price, K., Han, B., Selzler, K., Aisen, P., Cummings, J., Raskin, J., & Mohs, R. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140792 · Cited by 82
Self-citationDimitriadis, S. I., Laskaris, N., Bitzidou, M. P., Tarnanas, I., & Tsolaki, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00350 · Cited by 89
Wang, L., & Mao, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052360 · Cited by 97
“However, higher doses may lead to increased occurrence of side effects like microhemorrhages that have been observed during clinical trials [124,133].”
BackgroundAmyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?
Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81
“Solanezumab, another humanized monoclonal antibody, was adequately tolerated, but failed to improve cognition and disability in two phase III trials (69).”
Egan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0520-1 · Cited by 81
Self-citationTen Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“Solanezumab did not improve cognitive function in the two major phase III trials [137], but if one analyses the combined data there is a positive effect on cognition that should be explored further [138, 139].”
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Loeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
Avgerinos, K. I., Manolopoulos, A., Ferrucci, L., & Kapogiannis, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75204-8 · Cited by 95
“The effect sizes for these improvements were very small ( 0.2) and corresponded to NNTs of 22, 20, and 35, respectively.”
InfluentialCognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
Liu-Seifert, H., Initiative, T. A. D. N., Siemers, E., Price, K., Han, B., Selzler, K. J., Henley, D., Sundell, K., Aisen, P., Cummings, J., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142508 · Cited by 77
Self-citationClark, D. G., McLaughlin, P. M., Woo, E., Hwang, K., Hurtz, S., Ramirez, L., Eastman, J., Dukes, R., Kapur, P., DeRamus, T. P., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.001 · Cited by 80
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Shaw, L. M., Waligorska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 79
“For quantitative analysis, images were fitted to a PET template, and a composite standard uptake value ratio (SUVR) was also derived from the average estimate of florbetapir F 18 retention in six cortical volumes of interest (frontal, temporal and parietal cortex, anterior and posterior cingulate, and precuneus) relat…”
BackgroundInfluentialSelf-citationBurns, T. C., Li, M. D., Mehta, S., Awad, A. J., & Morgan, A. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.021 · Cited by 79
Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160216 · Cited by 77
DiFrancesco, J. C., Longoni, M., & Piazza, F. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00207 · Cited by 78
Liu, A., Jain, N., Vyas, A., & Lim, L. W. (2015) · eLife · doi:10.7554/elife.04803 · Cited by 76
Zhao, Y., Chen, X., Wu, Y., Wang, Y., Li, Y., & Xiang, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00140 · Cited by 83
“However, there are no effective therapies for AD involving pharmacological agents that target either Aβ or tau aggregation inhibitors (Doody et al., 2014; Salloway et al., 2014; Lovestone et al., 2015; Gauthier et al., 2016).”
BackgroundAnti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
Castello, M. A., Jeppson, J. D., & Soriano, S. (2014) · BMC Neurology · doi:10.1186/s12883-014-0169-0 · Cited by 77
Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
Hunter, S., & Brayne, C. (2017) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-017-0066-3 · Cited by 77
“Following the failure of both Bapineuzumab [51, 52] and Solanezumab [50] in phase III clinical trials, refinements to the therapeutic approach call for earlier, perhaps preventative, use of the antibodies during the prodromal phase of AD, i.e. where a high amyloid signal is seen on MRI but before any cognitive change…”
BackgroundInfluentialPreclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 77
“possible efficacy of disease modifying drugs in the early clinical stage of AD [24,27].”
BackgroundChun, H., Marriott, I., Lee, C. J., & Cho, H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00797 · Cited by 77
“These animal models have, therefore, been widely used to test potential AD therapies, but more than 20 agents that have shown promise in these models have failed in clinical trials (1, 2), raising suggestions that amyloid and tau may need to be targeted decades before clinical symptoms appear, and causing some to even…”
BackgroundJeremic, D., Navarro-López, J. D., & Jiménez-Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 77
Lessons from immunotherapy for Alzheimer disease
Wang, Y. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.44 · Cited by 87
Scholtzova, H., Chianchiano, P., Pan, J., Sun, Y., Goñi, F., Mehta, P. D., & Wisniewski, T. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0101-2 · Cited by 77
Barnes, D. E., Mehling, W. E., Wu, E. Y., Beristianos, M. H., Yaffe, K. S., Skultety, K. M., & Chesney, M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0113367 · Cited by 94
Hampel, H., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S., & Lista, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 75
Self-citationMolecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region
Choi, T. S., Lee, H. J., Han, J. Y., Lim, M. H., & Kim, H. I. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08584 · Cited by 76
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 75
ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy
Marco-Contelles, J., Unzeta, M., Bolea, I., Esteban, G., Ramsay, R. R., Romero, A., Martínez-Murillo, R., Carreiras, M. C., & Ismaili, L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00294 · Cited by 75
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75
“This article focuses on bapineuzumab and solanezumab because they share a mechanism of action (passive clearance of amyloid b, although targeting different portions of the peptide) and they both completed large Phase III trials that failed to detect clinically relevant treatment effects [31,32].”
BackgroundWebster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 74
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
“Indeed, solanezumab, another humanized monoclonal IgG1 Ab acting against the mid-region of Aβ, failed in clinical trial (Doody et al., 2014) but seems to have some cognitive benefits in the MCI stage of the disease (Panza et al.”
BackgroundBouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 79
Lu, K. P., Kondo, A., Albayram, Ö., Herbert, M. K., Liu, H., & Zhou, X. Z. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2027 · Cited by 78
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Mckean, N. E., Handley, R. R., & Snell, R. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313168 · Cited by 88
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“Instead, the hypothesis has been challenged by failures of several Phase III clinical trials aimed at inhibiting Ab production (secretase inhibitors) [27] or increasing its clearance from the brain (anti-Ab immunotherapy) [28,29].”
BackgroundRygiel, K. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.194867 · Cited by 73
“[40] Therefore, the APOE database, used in the GeneMatch program, will expedite recruitment of sufficiently large number of candidates in the early stages of AD.”
MethodInfluentialAtrial fibrillation, cognition and dementia: A review
Aldrugh, S., Sardana, M., Henninger, N., Saczynski, J. S., & McManus, D. D. (2017) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13261 · Cited by 78
Immunotherapy for Alzheimer’s disease: past, present and future
Spencer, B., & Masliah, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00114 · Cited by 72
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy
Sakai, K., Boche, D., Carare, R., Johnston, D., Holmes, C., Love, S., & Nicoll, J. A. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1340-9 · Cited by 72
Hasegawa, M. (2016) · Biomolecules · doi:10.3390/biom6020024 · Cited by 72
Rabins, P. V., Rovner, B. W., Rummans, T., Schneider, L. S., & Tariot, P. N. (2017) · Focus · doi:10.1176/appi.focus.15106 · Cited by 72
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Cacabelos, R. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1457645 · Cited by 70
The role of the immune system in driving neuroinflammation
Ní Chasaide, C., & Lynch, M. A. (2020) · Brain and Neuroscience Advances · doi:10.1177/2398212819901082 · Cited by 72
“Two of these trials that assessed solanezumab and bapineuzumab did not meet primary end points in improving clinical outcomes (Doody et al., 2014; Salloway et al., 2014; Vandenberghe et al., 2016).”
BackgroundGao, F., Zhao, J., Liu, P., Ji, D., Zhang, L., Zhang, M., Li, Y., & Xiao, Y. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.09.098 · Cited by 71
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
“This self-perpetuating mechanism of neurodegeneration is difficult to slow once established, and may partly account for the spate of notable clinical trial failures, particularly anti-amyloid therapy (Doody et al., 2014).”
Snow, A. D., Castillo, G. M., Nguyen, B. P., Choi, P. Y., Cummings, J. A., Cam, J. A., Hu, Q., Lake, T. P., Pan, W., Kastin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38645-0 · Cited by 82
Cremades, N., & Dobson, C. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.009 · Cited by 79
Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias
Buss, S. S., Fried, P. J., & Pascual‐Leone, Á. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000669 · Cited by 75
“Recent drug trial failures for Alzheimer’s disease and related dementias (ADRD) have left the field with a lack of disease-modifying therapies [5,6].”
BackgroundEngineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 90
“Antibody Therapeutics, 2022 315 more prespecified secondary analysis demonstrated that mild subjects benefit more from solanezumab treatment [30].”
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 75
Qiang, W., Cai, W., Yang, Q., Yang, L., Dai, Y., Zhao, Z., Yin, J., Li, Y., Li, Q., Wang, Y., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.10.041 · Cited by 72
Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review
Liao, H., Zhu, Z., & Peng, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00188 · Cited by 74
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
Vilaplana, E., Rodriguez-Vieitez, E., Ferreira, D., Montal, V., Almkvist, O., Wall, A., Lleó, A., Westman, E., Graff, C., Fortea, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009405 · Cited by 69
Antibodies and protein misfolding: From structural research tools to therapeutic strategies
Genst, E. D., Messer, A. C., & Dobson, C. M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.08.016 · Cited by 77
Investigational drugs in Alzheimer's disease: current progress
Berk, C., Paul, G., & Sabbagh, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.905542 · Cited by 69
An update on drug treatment options of Alzheimer's disease
Allgaier, M. (2014) · Frontiers in Bioscience · doi:10.2741/4285 · Cited by 69
Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.003 · Cited by 69
“In patients with mild-to-moderate AD, bapineuzumab did not improve clinical outcomes [4] and solanezumab did not significantly improve cognitive or functional ability [5].”
BackgroundKoychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170129 · Cited by 69
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Perng, C., Chang, Y., & Tzang, R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4867-y · Cited by 76
Sang, S., Pan, X., Chen, Z., Zeng, F., Pan, S., Liu, H., Jin, L., Fei, G., Wang, C., Ren, S., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0354-2 · Cited by 69
You, M., Pan, Y., Liu, Y., Chen, Y., Wu, Y., Si, J., Wang, K., & Hu, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00428 · Cited by 73
“In addition, recent documents showed that Aβ immunotherapy could not improve cognitive deficits in AD patients (Doody et al., 2014).”
BackgroundGenome-wide association identifies the first risk loci for psychosis in Alzheimer disease
DeMichele-Sweet, M. A. A., Klei, L., Creese, B., Harwood, J. C., Weamer, E. A., McClain, L., Sims, R., Hernandez, I., Moreno-Grau, S., Tárraga, L., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01152-8 · Cited by 64
“Diagnoses were made based on diagnostic evaluations, cognitive testing, and in some cases neuropathologic assessment, conducted during subjects’ participation in the following eight source programs as previously described: the Fundació ACE Barcelona Alzheimer Treatment and Research Center (ACE/GR@ACE) [31–33], a Conso…”
MethodInfluentiald’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 78
Hollow nanoarchitectures: Materials engineering, nanochemistry, and biomedical applications
Ghosh, S., Yang, C.-J., & Lai, J. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101634 · Cited by 76
Dukart, J., Sambataro, F., Bertolino, A., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150570 · Cited by 68
Gupta, V., Gupta, V. B., Chitranshi, N., Gangoda, S. V. S., Wall, R. V., Abbasi, M., Golzan, M., Dheer, Y., Shah, T. M., Avolio, A. P., et al. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2295-x · Cited by 75
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Kile, S., Au, W., Parise, C., Rose, K., Donnel, T., Hankins, A., Chan, M., & Ghassemi, A. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311486 · Cited by 67
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain
Blanchard, J., Victor, M. B., & Tsai, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00578-6 · Cited by 74
Lim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 90
Blackburn, D. J., Wakefield, S., Shanks, M. F., Harkness, K., Reuber, M., & Venneri, A. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu029 · Cited by 67
Fine‐tuning PERK signaling for neuroprotection
Halliday, M., Hughes, D., & Mallucci, G. R. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14112 · Cited by 67
Kaur, A., Mann, S., Kaur, A., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.058 · Cited by 69
Chiesa, S. T., Masi, S., Shipley, M. J., Ellins, E. A., Fraser, A. G., Hughes, A. D., Patel, R. S., Khir, A. W., Halcox, J. P., Singh-Manoux, A., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz189 · Cited by 66
Alzheimer’s disease: where next for anti-amyloid therapies?
Hardy, J., & De Strooper, B. (2017) · Brain · doi:10.1093/brain/awx059 · Cited by 67
Imbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 65
Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
Relkin, N. R. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0041-4 · Cited by 75
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Carlson, C., Siemers, E., Hake, A., Case, M., Hayduk, R., Suhy, J., Oh, J., & Barakos, J. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.004 · Cited by 65
Self-citationAntibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
Liu, J., Yang, B., Ke, J., Li, W., & Suen, W.-C. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0406-x · Cited by 74
“Results of two large, phase III trials involving over 2000 patients with mild to moderate AD from 16 countries (NCT00905372 [56] and NCT00904683 [56]) revealed that solanezumab failed to improve cognition or functional ability; however, on the basis of the secondary analysis findings of these two phase III trials, sub…”
BackgroundPrion-like mechanisms and potential therapeutic targets in neurodegenerative disorders
Hasegawa, M., Nonaka, T., & Masuda‐Suzukake, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.010 · Cited by 76
Assessing quality of life in Alzheimer's disease: Implications for clinical trials
Kahle‐Wrobleski, K., Ye, W., Henley, D. B., Hake, A. M., Siemers, E., Chen, Y., & Liu‐Seifert, H. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.11.004 · Cited by 71
Self-citation
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.